Emerging Peptide And Oligonucleotide CDMO Market Trends: Strategic Partnerships In Peptide And Oligonucleotide CDMO Market Boost Technological Capabilities And Market Reach Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Peptide And Oligonucleotide CDMO Market Size Growth Forecast: What to Expect by 2025?
In recent years, the peptide and oligonucleotide cdmo market has witnessed a swift escalation in its size. From $2.16 billion in 2024, it is projected to surge up to $2.42 billion in 2025 with a compound annual growth rate (CAGR) of 11.8%. The historic growth has been primarily driven by a surge in the requirement of therapeutic agents, improvements in synthesis and manufacturing, personalized medicine trends, enforcement of regulatory guidelines as well as the heightened focus on antiviral peptides and mRNA vaccines. This highlights the significance of oligonucleotides in vaccine development.

How Will the Peptide And Oligonucleotide CDMO Market Size Evolve and Grow by 2029?
Anticipating a swift expansion in the forthcoming years, the peptide and oligonucleotide CDMO market is projected to hit a value of "$3.69 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 11.2%. This expected growth during the projection period is a result of increasing demand for customised medication, advancements in biotechnological fields, widening application scopes, increased outsourcing, and the escalating challenge of chronic diseases. The future trends for this period are predicted to be customised therapy approaches, technological growth, challenges in quality control, global market growth and enhanced collaborations amongst biopharmaceutical businesses.

View the full report here:
https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

What Drivers Are Propelling the Growth of Peptide And Oligonucleotide CDMO Market Forward?
As the adoption of personalized healthcare continues to grow, it's anticipated that it will trigger the expansion of the peptide and oligonucleotide CDMO markets. Personalized medicine, which is a healthcare strategy that adjusts medical decisions and treatments to particular details such as genetics, environment, and lifestyle, has seen its adoption blossom due to several elements including improvements in genomic technologies, a heightened comprehension of disease mechanisms at the molecular level, and the need for treatment options which are more effective, targeted, and adapted to the patients' unique genetic makeups and medical pasts. Organisations involved in contract development and manufacturing like peptide and oligonucleotide CDMOs are instrumental in personalized medicine as they produce customized therapeutic peptides and oligonucleotides that cater to individual patient requirements. To illustrate, in February 2024, the Personalized Medicine Coalition, a UK organization advocating for the application of personalized medicine, reported that the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has approved 16 new personalized treatments specifically aimed at patients suffering from rare diseases, a significant rise from 6 in 2022. Hence, the expansion of personalized medicine is fuelling the growth of the peptide and oligonucleotide CDMO market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Are the Key Trends Driving Peptide And Oligonucleotide CDMO Market Growth?
Peptide and oligonucleotide CDMO market's major players are strategically partnering to broaden their service range, advance their technology, and extend their market visibility. Such partnerships are mutual agreements between two entities focusing on the creation and manufacturing of peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based CDMO, formed a partnership with Numaferm GmbH, a biotech company based in Germany, for peptide creation and production. The objective of this collaboration is to leverage PolyPeptide's cGMP manufacturing capabilities and market entrance along with Numaferm's proficiency in environmentally friendly peptide production and biochemical production platforms. The collaboration aims to collaboratively investigate the development of appropriate peptide candidates aiming for a greener production of peptide-based APIs.

What Are the Key Segments in the Peptide And Oligonucleotide CDMO Market?
The peptide and oligonucleotide cdmo market covered in this report is segmented -

1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Who Are the Key Players Shaping the Peptide And Oligonucleotide CDMO Market's Competitive Landscape?
Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

What Geographic Markets Are Powering Growth in the Peptide And Oligonucleotide CDMO Market?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15892

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.